Resistance to TRAIL and how to surmount it

Anticancer Effects of the Nitric Oxide-Modified Saquinavir Derivative Saquinavir-NO against Multidrug-Resistant Cancer Cells

(2015) Florian Rothweiler et al.   NEOPLASIA

The new and less toxic protease inhibitor saquinavir–NO maintains anti-HIV-1 properties in vitro indistinguishable from those of the parental compound saquinavir

(2011) Filippo Canducci et al.   ANTIVIRAL RESEARCH

Tumor microenvironment is multifaceted

(2011) Catherine Sautès-Fridman et al.   CANCER AND METASTASIS REVIEWS

Combined inhibition of DNA methyltransferase and histone deacetylase restores caspase-8 expression and sensitizes SCLC cells to TRAIL

(2011) Vitaliy O. Kaminskyy et al.   CARCINOGENESIS

In vitro and in vivo anticancer action of Saquinavir-NO, a novel nitric oxide-derivative of the protease inhibitor saquinavir, on hormone resistant prostate cancer cells

(2011) Marco Donia et al.   CELL CYCLE

Cell-surface galectin-3 confers resistance to TRAIL by impeding trafficking of death receptors in metastatic colon adenocarcinoma cells

(2011) N Mazurek et al.   CELL DEATH AND DIFFERENTIATION

Immunity, Inflammation, and Cancer

(2010) Sergei I. Grivennikov et al.   CELL

TRAIL and Doxorubicin Combination Induces Proapoptotic and Antiangiogenic Effects in Soft Tissue Sarcoma In vivo

(2010) S. Wang et al.   CLINICAL CANCER RESEARCH

Molecular Pathways Linking Inflammation and Cancer

(2010) A. Mantovani   CURRENT MOLECULAR MEDICINE

Cytotoxic and immune-sensitizing properties of nitric oxide-modified saquinavir in iNOS-positive human melanoma cells

(2010) Sanja Mijatovic et al.   JOURNAL OF CELLULAR PHYSIOLOGY

The TRAIL to Viral Pathogenesis: The Good, the Bad and the Ugly

(2009) Nathan Cummins et al.   CURRENT MOLECULAR MEDICINE

TNF-related apoptosis-inducing ligand (TRAIL): A new path to anti-cancer therapies

(2009) Peter A. Holoch et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Death receptors: Targets for cancer therapy

(2009) Zafar Mahmood et al.   EXPERIMENTAL CELL RESEARCH

Regulation of dendritic cell survival and cytokine production by osteoprotegerin

(2009) Takahiro Chino et al.   JOURNAL OF LEUKOCYTE BIOLOGY

The antitumor properties of a nontoxic, nitric oxide-modified version of saquinavir are independent of Akt

(2009) D. Maksimovic-Ivanic et al.   MOLECULAR CANCER THERAPEUTICS

Non-genetic origins of cell-to-cell variability in TRAIL-induced apoptosis

(2009) Sabrina L. Spencer et al.   NATURE

TRAIL receptor signalling and modulation: Are we on the right TRAIL?

(2008) Devalingam Mahalingam et al.   CANCER TREATMENT REVIEWS

TRAIL receptor-targeted therapeutics: Resistance mechanisms and strategies to avoid them

(2008) A THORBURN et al.   DRUG RESISTANCE UPDATES

TRAIL-R deficiency in mice enhances lymph node metastasis without affecting primary tumor development

(2008) Anne Grosse-Wilde et al.   JOURNAL OF CLINICAL INVESTIGATION

TRAIL-R deficiency in mice promotes susceptibility to chronic inflammation and tumorigenesis

(2008) Niklas Finnberg et al.   JOURNAL OF CLINICAL INVESTIGATION

Anti-HIV drugs for cancer therapeutics: back to the future?

(2008) Warren A Chow et al.   LANCET ONCOLOGY

TRAIL Resistance of Breast Cancer Cells Is Associated with Constitutive Endocytosis of Death Receptors 4 and 5

(2008) Y. Zhang et al.   MOLECULAR CANCER RESEARCH

Interleukin-8 signaling attenuates TRAIL- and chemotherapy-induced apoptosis through transcriptional regulation of c-FLIP in prostate cancer cells

(2008) C. Wilson et al.   MOLECULAR CANCER THERAPEUTICS